aiTBS for Relieving NSSI in Depressive Patients
Accelerated Intermittent Theta Burst Stimulation for the Treatment of Non-suicidal Self-injury in Patients With Unipolar Depression and Bipolar Depression: a Sham-controlled Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Renrong Wu, M.D. Ph.D
- Phone Number: +8615874179855
- Email: wurenrong@csu.edu.cn
Study Contact Backup
- Name: Jing Huang, M.D.
- Email: jinghuangserena001@csu.edu.cn
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410011
- Recruiting
- Mental Health Institute of Second Xiangya Hospital,CSU
-
Contact:
- Renrong Wu, PhD, M.D
- Phone Number: 15874179855
- Email: wurenrong2013@163.com
-
Contact:
- Jing Huang, MD
- Email: jinghuangserena001@csu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Documentation of DSM-5 criteria for current major depressive disorder (MDD) or bipolar disorder (BD) will be required for study entry.
- Ages between 12 and 18 years
- At least 1 caregivers to supervise the patient within 3 month.
- A score of greater than 17 on the HAM-D17.
- Occurrences of self injury behavior consistent with the DSM-5 criteria of NSSI more than 3 times in a month.
- Willingness to participate in the study and sign informed consents
Exclusion Criteria:
- Substance abusers such as psychoactive drugs or alcohol.
- Severe physical disability and unable to complete follow-up.
- Comorbid other major mental illnesses that meet the DSM-5 criteria, such as schizophrenia, mental retardation, dementia, severe cognitive impairment, attention deficit hyperactivity disorder, etc.
- Currently in a manic episode, YMRS>12; rapid-cycling bipolar disorder, bipolar disorder with mixed features.
- Suffering from any severe physical disease, neurological disease, traumatic brain injury, etc, that affects the structure or function of the brain in the lifetime.
- Unable to read, understand and complete the assessment or to cooperate with the investigators.
- Any implants covering a pacemaker, metallic or magnetic objects in the body, or other conditions not suitable for rTMS.
- A history or family history of epilepsy and other contraindications to TMS.
- Daily use of benzodiazepines (more than 2mg/d), theophylline, stimulants such as methylphenidate, anticonvulsants, bupropion, etc.
- Those who have received systematic psychotherapy (interpersonal relationship therapy, dynamic therapy, cognitive behavioral therapy) within 3 months before baseline.
- Other examination abnormalities considered to be inappropriate by investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: active stimulation
Active Intermittent theta burst stimulation to the dorsolateral prefrontal cortex; 5 sessions per day, for 5 days.
|
MagPro X100
|
|
Sham Comparator: Sham stimulation
Sham stimulation to the dorsolateral prefrontal cortex; 5 sessions per day, for 5 days.
|
MagPro X100
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in the Deliberate Self-Harm Inventory (DSHI)
Time Frame: Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
Containing one subscale ranging from 0 to 57 to measure the frequencies of NSSI behavior and one subscale ranging from 0 to 76 to measure the severity of NSSI behavior.
|
Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in number of occurrences of Non-Suicidal Self Injurious ideation Through SITBI-R
Time Frame: Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
The frequency of NSSI thoughts during the latest week
|
Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
|
Changes in likelihood of future Non-Suicidal Self Injury Through SITBI-R
Time Frame: Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
Range from 0-4, higher score indicates more likelihood to conduct NSSI in the future
|
Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
|
Changes in the 17-item Hamilton Rating Scale for Depression (HAMD-17)
Time Frame: Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
This will be measured as both a continuous variable (scores on HAMD-17 ) and a categorical one (i.e. the response rates of >50% reduction from baseline HAMD-17 and remission rates defined as HAMD-17 <7).
|
Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
|
Changes in Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
Range from 0-21, higher score indicates severe poorer sleep quality
|
Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
|
Changes in Hamilton Anxiety Scale (HAMA)
Time Frame: Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
Range from 0-56, higher score indicates more severe symptoms
|
Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
|
Changes in Young's Mania Scale (YMRS)
Time Frame: Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
Range from 0-60, higher score indicates more severe symptoms
|
Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
|
Changes in the subscale of addiction of NSSI from OSI (Ottawa self-injury inventory)
Time Frame: Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
Range from 0- 28, higher score indicates higher addiction.
|
Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
|
Changes in Barratt Impulsiveness Scale-11 (BIS-11)
Time Frame: Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
Range from 26-104, higher score indicates higher impulsivity
|
Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
|
Changes in cerebral blood flow of PFC through Near Infrared Spectroscopy (fNIRS)
Time Frame: Baseline, after 5 treatment days
|
Measuring the hemoglobin concentration of cerebral cortex during resting state and verbal fluency test.
|
Baseline, after 5 treatment days
|
|
Changes in Beck Suicidal Scale Inventory (BSI)
Time Frame: Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
Range from 0- 38, higher score indicates more severe suicide ideation.
|
Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
|
Changes in The Clinical Global Impression (CGI)
Time Frame: Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
Measuring the symptom severity, overall improvement, and therapeutic response to intervention.
|
Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
|
Changes in the Deliberate Self-Harm Inventory-ideation (DSHI-ideation)
Time Frame: Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
Range from 0 to 57 to measure the frequency of NSSI ideation
|
Baseline, after 5 treatment days, 2 week and 4 week post-treatment
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The retrospect of NSSI behavior
Time Frame: Baseline
|
Measured by Ottawa self-injury inventory (OSI), including reasons, addiction, site of NSSI, etc.
|
Baseline
|
|
Borderline features of patients with NSSI
Time Frame: Baseline
|
Measured by The Borderline Personality Feature Scale for Children - 11 (BPFS-C-11) ranging from 24 to 120
|
Baseline
|
|
Fundelmental parental style of caregivers of patients with NSSI
Time Frame: Baseline
|
Measured by the Parental Bonding Instrument (PBI) containing two subscales ranging from 0 to 75 for both mother and father version.
|
Baseline
|
|
Safety and tolerance of the intervention
Time Frame: After 5 treatment days
|
Recording any side effects in the adverse event record form (AERF).
|
After 5 treatment days
|
|
Child maltreatment of patients with NSSI
Time Frame: Baseline
|
Measured by the Childhood Trauma Questionnaire (CTQ) ranging from 25 to 125.
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TMS20220425
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.